3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH

US8957068B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Thomas Raymond Caferro · Abington, US
• Young Shin Cho · Cambridge, US
• Abran Q. Costales · Corona, US
• Huangshu Lei · Ann Arbor, US
• Francois Lenoir · Waltham, US
• Julian Levell · Arlington, US
• Gang Liu · Sugar Land, US
• Mark G. Palermo · Rindge, US
• Keith B. Pfister · Emeryville, US
• Martin Sendzik · Belmont, US
• Cynthia Shafer · El Sobrante, US
• Michael David Shultz · Lexington, US
• Troy Douglas Smith · Nashua, US
• James Sutton · Princeton Junction, US
• Bakary-Barry Toure · Weston, US
• Fan Yang · Brookline, US
• Qian Zhao · Louisville, US

Key dates

• Filing date: Sep 26, 2012
• Grant date: Feb 17, 2015
• Expiry date: Sep 26, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.